Company intelligence / Profile preview

AUM Cardiovascular

Northfield, Minnesota, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

The CADence device by AUM Cardiovascular has received FDA clearance as a non-invasive acoustic and ECG diagnostic tool to help physicians detect physiological and pathological heart murmurs. Clinical studies show that CADence performs comparably to nuclear stress tests in ruling out obstructive coronary artery disease. The company continues to pursue additional regulatory clearances for broader use in detecting coronary artery disease using proprietary algorithms.

Therapeutic areas: Cardiovascular
Modalities: DeviceDiagnostic device (acoustic and ECG-based)
Industry: Physiological Monitoring

Partnerships

AT&T (technology/data partnership)

Beyond the preview

Go deeper on AUM Cardiovascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AUM Cardiovascular.

Explore the full profile